Cargando…

Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept

INTRODUCTION: Hepatitis B virus (HBV) reactivation in kidney transplant recipients has been reported in 3% to 9% of anti-HBc antibody (HBcAb)-positive HBs antigen (HBsAg)-negative patients. It has not been studied in patients receiving belatacept, a selective costimulation blocker. METHODS: We perfo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwarz, Chloë, Morel, Antoine, Matignon, Marie, Grimbert, Philippe, Rondeau, Eric, Ouali, Nacera, François, Hélène, Mesnard, Laurent, Petit-Hoang, Camille, Rafat, Cédric, Dahan, Karine, Luque, Yosu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403656/ https://www.ncbi.nlm.nih.gov/pubmed/37547512 http://dx.doi.org/10.1016/j.ekir.2023.05.005

Ejemplares similares

Additional Benefits of Rituximab and Plasma Exchange on Top of Standard Induction Therapy in Kidney Transplant Recipients With a Negative CDC Crossmatch but High Preformed Donor Specific Antibody Titer
por: Mohamadou, Inna, et al.
Publicado: (2023)

COVID-19-associated acute kidney injury: after the tubule and the glomerulus, now the vessel?
por: Mayet, Valentin, et al.
Publicado: (2020)

Immunoadsorption-Based HLA Desensitization in Patients Awaiting Deceased Donor Kidney Transplantation: An Interventional, Non-Randomised, Single Cohort Study
por: Bureau, Côme, et al.
Publicado: (2023)

Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients
por: El Sakhawi, Karim, et al.
Publicado: (2020)

Management of Undocumented Immigrants With End-Stage Kidney Disease in 2 Academic Hospitals in Paris
por: Le Flécher, Arnaud, et al.
Publicado: (2021)

Three-Year Outcomes in Kidney Transplant Recipients Switched From Calcineurin Inhibitor-Based Regimens to Belatacept as a Rescue Therapy
por: Morel, Antoine, et al.
Publicado: (2022)

Exome-First Strategy in Adult Patients With CKD: A Cohort Study
por: Doreille, Alice, et al.
Publicado: (2022)

Eculizumab and aHUS: Spotlight on Patient-Centered Care
por: Rafat, Cédric, et al.
Publicado: (2020)

Noninvasive screening of vancomycin-associated cast nephropathy
por: Rafat, Cédric, et al.
Publicado: (2022)

Belatacept inhibit human B cell germinal center development in immunodeficient mice
por: Samson, Chloé, et al.
Publicado: (2023)

Ockham’s razor defeated: about two atypical cases of hemolytic uremic syndrome
por: Schwarz, Chloe, et al.
Publicado: (2020)

Time-Limited Therapy with Belatacept in Kidney Transplant Recipients
por: Letellier, Thibault, et al.
Publicado: (2022)

Optimization of de novo belatacept‐based immunosuppression administered to renal transplant recipients
por: Kirk, Allan D., et al.
Publicado: (2020)

Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept
por: Chavarot, Nathalie, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019)

Home dialysis machine use for emergency dialysis during the COVID-19 pandemic
por: Mousseaux, Cyril, et al.
Publicado: (2020)

Phenotypic and Transcriptomic Lymphocytes Changes in Allograft Recipients After Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients
por: Pilon, Caroline, et al.
Publicado: (2020)

Belatacept conversion in African American kidney transplant recipients with severe renal dysfunction
por: Snyder, Heather S, et al.
Publicado: (2016)

Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
por: Tawhari, Ibrahim, et al.
Publicado: (2022)

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study
por: Bremer, Sara, et al.
Publicado: (2009)

Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
por: Coscia, Lisa, et al.
Publicado: (2023)

Immune Response Post–SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept
por: Noble, Johan, et al.
Publicado: (2021)

ATG-Fresenius increases the risk of red blood cell transfusion after kidney transplantation
por: Sebti, Maria, et al.
Publicado: (2022)

Belatacept: Good, but not good enough?
por: Parameswaran, Sreejith, et al.
Publicado: (2012)

Belatacept: the challenges with transformational drugs
por: Vincenti, Flavio
Publicado: (2017)

Acute Kidney Injury After High Doses of Amoxicillin
por: Mousseaux, Cyril, et al.
Publicado: (2020)

Phase I study of single‐dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients
por: Moudgil, Asha, et al.
Publicado: (2019)

The blockade of T-cell co-stimulation as a therapeutic stratagem for immunosuppression: Focus on belatacept
por: Snanoudj, Renaud, et al.
Publicado: (2007)

Impact of a Dedicated Pretransplant Infectious Disease Consultation on Respiratory Tract Infections in Kidney Allograft Recipients: A Retrospective Study of 516 Recipients
por: Feredj, Elsa, et al.
Publicado: (2023)

HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers
por: Joher, Nizar, et al.
Publicado: (2021)

Pilot Analysis of Late Conversion to Belatacept in Kidney Transplant Recipients for Biopsy-Proven Chronic Tacrolimus Toxicity
por: Gupta, Shruti, et al.
Publicado: (2018)

Belatacept associated - cytomegalovirus retinitis in a kidney transplant recipient: a case report and review of the literature
por: Deliège, Pierre-Guillaume, et al.
Publicado: (2020)

Belatacept in Kidney Transplantation: What Are the True Benefits? A Systematic Review
por: Lombardi, Yannis, et al.
Publicado: (2022)

Belatacept: A worthy alternative to cyclosporine?
por: Melvin, George, et al.
Publicado: (2012)

Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014)

Belatacept in renal transplantation—quo vadis?
por: Westhoff, Timm H.
Publicado: (2016)

Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study
por: Matignon, Marie, et al.
Publicado: (2017)

Efficacy and Safety of Belatacept Treatment in Renal Allograft Recipients at High Cardiovascular Risk—A Single Center Experience
por: Neuwirt, Hannes, et al.
Publicado: (2019)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_73qnkuff61p9f3um8fan7aqf51